DK0970213T3 - Dödsdomæneholdig receptor - Google Patents

Dödsdomæneholdig receptor

Info

Publication number
DK0970213T3
DK0970213T3 DK98912966T DK98912966T DK0970213T3 DK 0970213 T3 DK0970213 T3 DK 0970213T3 DK 98912966 T DK98912966 T DK 98912966T DK 98912966 T DK98912966 T DK 98912966T DK 0970213 T3 DK0970213 T3 DK 0970213T3
Authority
DK
Denmark
Prior art keywords
death domain
containing receptor
proteins
antagonists
receptor
Prior art date
Application number
DK98912966T
Other languages
English (en)
Inventor
Guo-Liang Yu
Jian Ni
Reiner L Gentz
Jeffrey Y Su
Craig A Rosen
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26717514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0970213(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of DK0970213T3 publication Critical patent/DK0970213T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DK98912966T 1997-03-17 1998-03-17 Dödsdomæneholdig receptor DK0970213T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4084697P 1997-03-17 1997-03-17
US5402197P 1997-07-29 1997-07-29
PCT/US1998/005377 WO1998041629A2 (en) 1997-03-17 1998-03-17 Death domain containing receptor 5

Publications (1)

Publication Number Publication Date
DK0970213T3 true DK0970213T3 (da) 2007-05-21

Family

ID=26717514

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98912966T DK0970213T3 (da) 1997-03-17 1998-03-17 Dödsdomæneholdig receptor

Country Status (15)

Country Link
US (2) US7803615B1 (da)
EP (1) EP0970213B1 (da)
JP (2) JP4330180B2 (da)
KR (1) KR100527638B1 (da)
CN (2) CN1624128A (da)
AT (1) ATE352618T1 (da)
AU (1) AU747635B2 (da)
CA (2) CA2285040C (da)
DE (1) DE69836956T2 (da)
DK (1) DK0970213T3 (da)
ES (1) ES2281126T3 (da)
HK (1) HK1025352A1 (da)
NZ (2) NZ337795A (da)
PT (1) PT970213E (da)
WO (1) WO1998041629A2 (da)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US7528239B1 (en) * 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
CN1624128A (zh) 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
JP2001511653A (ja) * 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EP1012179A2 (en) * 1997-09-12 2000-06-28 Apotech R&D S.A. Cysteine rich receptors: trail
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
CA2328498A1 (en) * 1998-06-12 1999-12-16 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same____________________________________
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
CA2369371A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
AU6928200A (en) * 1999-08-25 2001-03-19 Genome Therapeutics Corporation A transmembrane trap for isolating membrane bound proteins
CA2399391A1 (en) * 2000-02-11 2001-08-16 Genetics Institute, Llc. Trade molecules and uses related thereto
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
EP1303293B1 (en) 2000-07-27 2008-12-03 Genentech, Inc. Sequential administration of cpt-11 and apo-2l polypeptide
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
WO2002094880A1 (en) 2001-05-18 2002-11-28 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies
NZ529359A (en) 2001-05-25 2007-04-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7252994B2 (en) 2001-07-03 2007-08-07 Genentech, Inc. Human DR4 antibodies and uses thereof
WO2003011318A1 (en) * 2001-08-01 2003-02-13 Genset S.A. Agonists and antagonists of famoset for use in the treatment of metabolic disorders
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
EP1439225A4 (en) 2001-10-04 2005-10-26 Kansai Tech Licensing Org Co DR5-GEN PROMOTER AND SIAH-1-GEN PROMOTER
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
DE60237841D1 (de) 2001-11-13 2010-11-11 Genentech Inc Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
NZ532881A (en) * 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
US20040101915A1 (en) * 2002-06-18 2004-05-27 Irm Llc, A Delaware Limited Liability Company Diagnosis and treatment of chemoresistant tumors
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
CA2575755C (en) * 2004-08-06 2014-04-08 Genentech, Inc. Assays and methods using biomarkers
CN101035912A (zh) 2004-08-06 2007-09-12 健泰科生物技术公司 使用生物标志的测定法和方法
EP1802660A2 (en) * 2004-09-08 2007-07-04 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
NZ553174A (en) * 2004-09-08 2010-03-26 Genentech Inc Methods of using death receptor ligands Apo2L/Trail and CD20 antibodies
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2595440A1 (en) 2005-02-02 2006-08-10 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1915626B1 (en) * 2005-08-16 2011-11-09 Genentech, Inc. Apoptosis sensitivity to apo2l/trail by testing for galnac-t14 expression in cells/tissues
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20100105620A1 (en) 2008-10-10 2010-04-29 Anaphore, Inc. Polypeptides that bind Trail-R1 and Trail-R2
US8790663B2 (en) 2009-04-03 2014-07-29 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Antigenic determinants of human death receptor DR5
BR112012005485A2 (pt) 2009-09-10 2016-04-19 Lonza Biologics Plc método e sistema para a purificação de polipeptídeo
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
CN105050524B (zh) 2013-03-22 2018-04-03 皇家飞利浦有限公司 用于使用激光无创处理皮肤的设备
CN104693308B (zh) * 2013-12-05 2020-08-04 同济大学 感受胞内pH变化的Smad5蛋白及其应用
EP3323428A1 (en) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
CN108997503B (zh) * 2017-06-06 2021-07-23 深圳市中科艾深医药有限公司 人sDR5-Fc重组融合蛋白及其作为制备治疗生殖系统炎症的药物中的应用
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
CN1624128A (zh) 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
WO1998046643A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1032661A1 (en) 1997-06-18 2000-09-06 Genentech, Inc. Apo-2DcR
JP2002507127A (ja) 1997-06-26 2002-03-05 イミュネックス・コーポレーション Ｔｒａｉｌに結合するタンパク質
ATE429450T1 (de) 1999-05-28 2009-05-15 Genentech Inc Chimärische dr4 antikörper und ihre verwendung
WO2000075191A2 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Also Published As

Publication number Publication date
DE69836956T2 (de) 2007-10-31
US20020098550A1 (en) 2002-07-25
CN1624128A (zh) 2005-06-08
DE69836956D1 (de) 2007-03-15
US7803615B1 (en) 2010-09-28
AU747635B2 (en) 2002-05-16
CA2644454A1 (en) 1998-09-24
EP0970213B1 (en) 2007-01-24
WO1998041629A3 (en) 1998-10-29
CN1275162A (zh) 2000-11-29
WO1998041629A2 (en) 1998-09-24
CN1184315C (zh) 2005-01-12
JP4330180B2 (ja) 2009-09-16
EP0970213A2 (en) 2000-01-12
CA2285040C (en) 2009-01-27
KR100527638B1 (ko) 2005-11-23
NZ508381A (en) 2002-09-27
AU6763598A (en) 1998-10-12
ES2281126T3 (es) 2007-09-16
JP2001520513A (ja) 2001-10-30
PT970213E (pt) 2007-04-30
HK1025352A1 (en) 2000-11-10
KR20000076364A (ko) 2000-12-26
CA2285040A1 (en) 1998-09-24
NZ337795A (en) 2001-06-29
ATE352618T1 (de) 2007-02-15
JP2008081503A (ja) 2008-04-10

Similar Documents

Publication Publication Date Title
DK0970213T3 (da) Dödsdomæneholdig receptor
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
DE69834027D1 (de) Tumor-nekrose-faktor rezeptor 5
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2000066156A8 (en) Death domain containing receptor 5
DE69841140D1 (de) Interleukin-17 rezeptor-ähnliches protein
WO2001055308A3 (en) Nucleic acids, proteins, and antibodies
EP1003767A4 (en) TR10 RECEPTOR OF HUMAN TUMOR NECROSIS FACTOR
WO2001054472A8 (en) Nucleic acids, proteins, and antibodies
WO1999035262A3 (en) Apoptosis inducing molecule ii
WO2000067793A8 (en) Death domain containing receptor 4
ATE472599T1 (de) Chemokin alpha-5
EP1187842A4 (en) THE TR10 RECEPTOR OF THE HUMAN TUMOR NECROSE FACTOR
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2002057421A3 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies